In KRAS-mutated colorectal [92] and lung [93] adenocarcinoma cells, PI3K/AKT pathway activation is dependent on RTK–WT RAS signaling (see Section 3.3), and thus inhibition of RTK signaling should indirectly inhibit PI3K activation. This evidence concerns the gene KRAS and adenocarcinoma.